- Ut imperdiet leo id lorem fermentum consectetur.
- Ut vitae orci et dui varius tincidunt.
- Ut id magna non libero vestibulum pharetra ac faucibus nulla.
News & Trends - Biotechnology
Ex-Pfizer Julie Liu joins biotech Cerecin as new Vice President of R&D

Biotech News: Cerecin, a clinical-stage biotechnology company pioneering ketogenic neurotherapeutics, appoints Julie Liu as Vice President of R&D in Australia.
Julie will lead all chemical, manufacturing and controls (CMC) operations for Cerecin. She will oversee all formulation and drug product development for Cerecin’s lead compound tricaprilin, which is being studied in a currently enrolling Phase 2 study in migraine, and in upcoming studies in West Syndrome and Alzheimer’s disease.
Julie brings more than 20 years of experience in R&D, regulatory affairs, global product registration and strategic outsourcing, with experience spanning Australia, Europe and Asia Pacific.
Julie joins Cerecin from Pfizer Australia, where she led R&D, Product Design, Science and Technology and was a member of the Pfizer Complex Generics Advisory Board. Prior to Pfizer, she worked for Fresenius Kabi
in Germany as a Senior Vice President, Innovation and Development, Mature and Emerging Markets. Julie also worked at Sandoz in roles including global head of R&D and Regulatory for Oncology injectables, as well as Regional Head Asia Pacific, Middle East and Africa, where she was responsible for the Manufacture Science and Technology (MS&T) network and leadership.
You may also like Cerecin’s clinical advance in migraine treatment
Commenting on the appointment, Charles Stacey, CEO of Cerecin, said “We are pleased to have Julie join Cerecin’s executive team and believe her global experience, proven leadership and deep knowledge of the biopharma development and pharmaceutical science will be of huge value to our programmes.”
Julie Liu added “Alzheimer’s and Migraine are two neurological illnesses with large unmet clinical need and significant disease burden for both patients and caregivers. I’m incredibly excited to be joining such a well-versed team of experienced researchers and scientists with the common goal of providing better treatment options for patients globally.”
Julie obtained a Bachelor of Pharmacy degree from Xi’an Jiaotong University China, and graduated from Monash University, Australia with a Master’s degree in Pharmaceutical Science.
Leadership & Management

The power of being an authentic leader
Leadership & Management: Welcome to Health Industry Hub’s Women in Leadership Series – connecting, engaging and empowering women in the […]
MoreDigital & Innovation

Data is the biggest challenge, and opportunity, for MedTech
Digital & Innovation: Medical technology is increasingly shaping the future of healthcare. The sector is also a growing part of […]
MoreNews & Trends - Medical Technology

Thermo Fisher acquisition to better serve its pharma and biotech clients
MedTech News: Thermo Fisher Scientific is buying clinical research services provider PPD for a hearty $17.4 billion, and that’s not its only acquisition this […]
MoreNews & Trends - Pharmaceuticals

First-in-class oncology drug candidate licensed by Aussie pharma
Pharma News: An Australian oncology-focused drug development company entered into a worldwide exclusive licensing agreement and a master services agreement […]
More